| All patients | Patients not admitted to hospital | Hospitalized, discharged alive | Hospitalized, deceased | ||||
---|---|---|---|---|---|---|---|---|
n = 58 | n = 22 | n = 22 | n = 14 | |||||
Demographics | ||||||||
 Age (years) | 67 | [12.5] | 64 | [11.5] | 71 | [18.5] | 68 | [8] |
 Sex (male) | 52% | (30) | 32% | (7) | 68% | (15) | 57% | (8) |
 Race (non-White) | 63% | (36/57) | 55% | (12) | 55% | 12 | 92% | (12) |
 BMI (kg/m2) | 27.6 | [7.9] | 26.1 | [5.3] | 28.2 | [10.2] | 29.5 | [9.9] |
 Obesity (BMI > 30 kg/m2) | 37% | (21/57) | 27% | (6) | 38% | (8/21) | 50% | (7) |
Comorbidities | ||||||||
 High cardiovascular risk profile (≥ 2 of hypertension, hyperlipidemia, diabetes) | 55% | (32) | 36% | (8) | 64% | (14) | 71% | (10) |
  Hypertension | 64% | (37) | 59% | (13) | 59% | (13) | 79% | (11) |
  Hyperlipidemia | 62% | (36) | 50% | (11) | 59% | (13) | 86% | (12) |
  Diabetes | 28% | (16) | 9% | (2) | 45% | (10) | 29% | (4) |
 Previous atherosclerotic complications (CAD and/or CVA) | 22% | (13) | 0% | (0) | 36% | (8) | 36% | (5) |
  Congestive heart failure | 12% | (7) | 0% | (0) | 14% | (3) | 29% | (4) |
  Current or former smoker | 37% | (21/57) | 27% | (6) | 38% | (8/21) | 50% | (7) |
 Lung disease (COPD, emphysema, asthma, bronchiectasis) | 21% | (12) | 18% | (4) | 27% | (6) | 14% | (2) |
 Chronic kidney disease (eGFR < 60 mL/min) | 24% | (14) | 23% | (5) | 27% | (6) | 21% | (3) |
  History of other malignancy | 9% | (5) | 5% | (1) | 5% | (1) | 21% | (3) |
  Number of comorbidities | 2 | [3] | 1 | [1.75] | 3 | [3] | 3.5 | [1.75] |
Concomitant medication | ||||||||
 Anticoagulation | 21% | (12) | 9% | (2) | 27% | (6) | 29% | (4) |
 Aspirin | 59% | (34) | 59% | (13) | 59% | (13) | 57% | (8) |
 Statin | 47% | (27) | 14% | (3) | 59% | (13) | 79% | (11) |
 ACE inhibitor or angiotensin II receptor blocker | 45% | (26) | 36% | (8) | 41% | (9) | 64% | (9) |
 Beta blocker | 34% | (20) | 9% | (2) | 50% | (11) | 50% | (7) |
 Metformin | 16% | (9) | 5% | (1) | 32% | (7) | 7% | (1) |
 Non-steroidal anti-inflammatory drug | 5% | (3) | 5% | (1) | 5% | (1) | 7% | (1) |
 Oral corticosteroids | 53% | (31) | 45% | (10) | 50% | (11) | 71% | (10) |
 COVID-19 confirmed by PCR at MSH | 71% | (41) | 59% | (13) | 86% | (19) | 64% | (9) |